2011 - ISBTS 2011 Symposium


Oral Communications 4: Intestinal Immunosuppression / Rejection

6.131 - Late onset acute rejection following intestinal transplantation (ITx) - a single centre experience

Presenter: Andrea, Pietrobattista, Birmingham, UK, United Kingdom
Authors: Andrea Pietrobattista1, Sara Gozzini1, Khalid Sharif1, Paolo Muiesan1, Darius Mirza1, Girish Gupte1


131
Late onset acute rejection following intestinal transplantation (ITx) - a single centre experience

Andrea Pietrobattista, Sara Gozzini, Khalid Sharif, Paolo Muiesan, Darius Mirza, Girish Gupte

Liver Unit including small bowel trasplantation, Birmingham Children Hospital, Birmingham, United Kingdom

Introduction and aim: Acute  rejection (AR) affects > 60% of ITx  between day 5- 60. Limited data exists about late onset AR (>6 months post-ITx). Aim of our study is to evaluate the incidence of late onset of AR in SBT.

Methods: Retrospective review of ITx 1998-2009 with confirmed histopathological diagnosesof  late onset AR. 57 patients for a total of 63 SBT were included in the study.

 Results: Of the 112 episodes of AR,  59 (52%) presented as late onset. 8 patients (12.6%), experienced the first episodes at least 6 months after the SBT with  2/8 after 24 months ( graft survival 75%).

Table 1:

 

Liver inclusive graft

Liver not included in graft

Treatment

No of patients

27

2

 

No of episodes

   Mild

   Moderate

   Severe

54

34

8

12

5

3

1

1

 

Single MP, ↑ IS

3 boluses MP, ↑IS, ± ATG/OKT3

ATG/OKT3, Campath

Median age to rejection from post-Tx

1,86

1,94

 

Chronic rejection

3

1

 

Re-transplantation

2

1

 

Survival

22

1

 

MP= Methylprenisolone 20 mg /kg to max of 400 mg

IS= Immunosuppression

Discussion: No graft has been removed as part of the treatment for late AR despite the higher incidence of a severe grade (20%) compared with the overall grading of late AR. Levels of IS prior to the episode of rejection reviewed were within the target range.

Conclusion: Late AR is not rare in SBT. Aggressive medical treatment of late onset AR is necessary for essential survival of the patient.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi